MannKind Corporation
Financials
Valuation Metrics
MannKind Corporation's Market Cap is $1.14B. At end of 2025 it was $1.73B. Ranked #2392 of 3,121 in US market (top 77%), #969 of 1,463 on NASDAQ (top 66%), #181 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.14B | US#2,392/3,121 Sec#181/266 |
| Revenue | $394M | US#2,363/3,121 Sec#86/266 |
| Net Income | $-44M | US—/3,121 Sec—/266 |
| Total Assets | $732M | US#2,609/3,121 Sec#128/266 |
| Net Assets | $-67M | US#2,960/3,121 Sec#251/266 |
| Employees | 592 | US#2,211/3,121 Sec#78/266 |
| Value | ||
| P/S | 2.89x | US#1,677/3,121 Sec#45/266 |
| EV/EBITDA | 46.06x | US#2,350/3,121 Sec#71/266 |
| FCF Yield | -1.63% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -5.96% | US#2,567/3,121 Sec#90/266 |
| Op. Margin | 1.97% | US#2,250/3,121 Sec#78/266 |
| Revenue Growth | 30.46% | US#425/3,121 Sec#63/266 |
| Earnings Growth | -232.98% | US#1,973/3,121 Sec#64/266 |
| Financial Health | ||
| Total Debt | $331M | US#2,069/3,121 Sec#75/266 |
| FCF | $-19M | US#2,417/3,121 Sec#94/266 |
| Cash | $53M | US#2,557/3,121 Sec#225/266 |
| Current Ratio | 1.72x | US#1,457/3,121 Sec#233/266 |
| Net Debt/EBITDA | 9.04x | US#2,334/3,121 Sec#81/266 |
| Performance | ||
| 1Y Return | -36.90% | US#2,694/3,121 Sec#230/266 |
| 1M Return | -19.36% | US#2,628/3,121 Sec#201/266 |
| From 52W High | -45.62% | US#2,594/3,121 Sec#205/266 |
| 1Y MDD | -63.28% | US#2,846/3,121 Sec#222/266 |
| Trading | ||
| Volume | 5,093,881 shares | US#647/3,121 Sec#62/266 |
| Trading Value | $18M | US#2,362/3,121 Sec#192/266 |
| Per Share | ||
| EPS | $-0.14 | US—/3,121 Sec—/266 |
| BPS | $-0.21 | US—/3,121 Sec—/266 |
Company Info
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.